A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status

Trial Profile

A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 May 2017

At a glance

  • Drugs CPI 613 (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 09 May 2017 Results published in the Cornerstone Pharmaceuticals Media Release.
    • 09 May 2017 According to a Cornerstone Pharmaceuticals media release, results of this phase I study published in the Lancet Oncology.
    • 13 Mar 2017 Planned primary completion date changed from 1 Apr 2016 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top